Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

NCT02493335 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Esophagitis

Interventions

DRUG: Budesonide 0.5mg orodispersible tablet twice daily
DRUG: Budesonide 1mg orodispersible tablet twice daily
DRUG: Placebo orodispersible tablet twice daily

Sponsor

Dr. Falk Pharma GmbH